JP2013523190A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013523190A5 JP2013523190A5 JP2013505183A JP2013505183A JP2013523190A5 JP 2013523190 A5 JP2013523190 A5 JP 2013523190A5 JP 2013505183 A JP2013505183 A JP 2013505183A JP 2013505183 A JP2013505183 A JP 2013505183A JP 2013523190 A5 JP2013523190 A5 JP 2013523190A5
- Authority
- JP
- Japan
- Prior art keywords
- toxin
- antibody
- antigen
- difficile
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 102
- 239000000427 antigen Substances 0.000 claims 83
- 102000036639 antigens Human genes 0.000 claims 82
- 108091007433 antigens Proteins 0.000 claims 82
- 241000193163 Clostridioides difficile Species 0.000 claims 76
- 101710084578 Short neurotoxin 1 Proteins 0.000 claims 76
- 101710182532 Toxin a Proteins 0.000 claims 76
- 101710182223 Toxin B Proteins 0.000 claims 64
- 108090000765 processed proteins & peptides Proteins 0.000 claims 42
- 229920001184 polypeptide Polymers 0.000 claims 39
- 102000004196 processed proteins & peptides Human genes 0.000 claims 39
- 125000003275 alpha amino acid group Chemical group 0.000 claims 32
- 230000003472 neutralizing effect Effects 0.000 claims 21
- 210000004408 hybridoma Anatomy 0.000 claims 16
- 230000002401 inhibitory effect Effects 0.000 claims 14
- 239000003053 toxin Substances 0.000 claims 14
- 231100000765 toxin Toxicity 0.000 claims 14
- 108700012359 toxins Proteins 0.000 claims 14
- 238000000034 method Methods 0.000 claims 13
- 210000004027 cell Anatomy 0.000 claims 12
- 230000001988 toxicity Effects 0.000 claims 11
- 231100000419 toxicity Toxicity 0.000 claims 11
- 230000001717 pathogenic effect Effects 0.000 claims 9
- 102000005962 receptors Human genes 0.000 claims 8
- 108020003175 receptors Proteins 0.000 claims 8
- 108091008324 binding proteins Proteins 0.000 claims 7
- 102000023732 binding proteins Human genes 0.000 claims 7
- 208000015181 infectious disease Diseases 0.000 claims 7
- 230000010534 mechanism of action Effects 0.000 claims 7
- 241001465754 Metazoa Species 0.000 claims 5
- 230000001147 anti-toxic effect Effects 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 108090000790 Enzymes Proteins 0.000 claims 4
- 102000004190 Enzymes Human genes 0.000 claims 4
- 239000003242 anti bacterial agent Substances 0.000 claims 4
- 230000002860 competitive effect Effects 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 230000003053 immunization Effects 0.000 claims 4
- 230000002163 immunogen Effects 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 229960005486 vaccine Drugs 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 241001112695 Clostridiales Species 0.000 claims 3
- 230000000903 blocking effect Effects 0.000 claims 3
- 210000004899 c-terminal region Anatomy 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 102100021324 5-azacytidine-induced protein 2 Human genes 0.000 claims 2
- 206010012735 Diarrhoea Diseases 0.000 claims 2
- 102000000340 Glucosyltransferases Human genes 0.000 claims 2
- 108010055629 Glucosyltransferases Proteins 0.000 claims 2
- 108090001007 Interleukin-8 Proteins 0.000 claims 2
- KGZHFKDNSAEOJX-WIFQYKSHSA-N Ramoplanin Chemical compound C([C@H]1C(=O)N[C@H](CCCN)C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C)C(=O)N[C@H](C(=O)O[C@@H]([C@@H](C(N[C@@H](C(=O)N[C@H](CCCN)C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)[C@H](C)O)C=1C=CC(O)=CC=1)C=1C=CC(O)=CC=1)[C@@H](C)O)C=1C=CC(O)=CC=1)=O)NC(=O)[C@H](CC(N)=O)NC(=O)\C=C/C=C/CC(C)C)C(N)=O)C=1C=C(Cl)C(O)=CC=1)C=1C=CC(O)=CC=1)[C@@H](C)O)C=1C=CC(O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=1)C1=CC=CC=C1 KGZHFKDNSAEOJX-WIFQYKSHSA-N 0.000 claims 2
- 108010059993 Vancomycin Proteins 0.000 claims 2
- YQNQNVDNTFHQSW-UHFFFAOYSA-N acetic acid [2-[[(5-nitro-2-thiazolyl)amino]-oxomethyl]phenyl] ester Chemical compound CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 YQNQNVDNTFHQSW-UHFFFAOYSA-N 0.000 claims 2
- 239000003899 bactericide agent Substances 0.000 claims 2
- 239000000022 bacteriostatic agent Substances 0.000 claims 2
- 238000010494 dissociation reaction Methods 0.000 claims 2
- 230000005593 dissociations Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000002255 enzymatic effect Effects 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 230000002209 hydrophobic effect Effects 0.000 claims 2
- 230000007246 mechanism Effects 0.000 claims 2
- 229960000282 metronidazole Drugs 0.000 claims 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims 2
- 229960002480 nitazoxanide Drugs 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 230000002797 proteolythic effect Effects 0.000 claims 2
- 229950003551 ramoplanin Drugs 0.000 claims 2
- 108010076689 ramoplanin Proteins 0.000 claims 2
- 229960003040 rifaximin Drugs 0.000 claims 2
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 claims 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 2
- 229960003165 vancomycin Drugs 0.000 claims 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims 2
- 230000035899 viability Effects 0.000 claims 2
- 102000011727 Caspases Human genes 0.000 claims 1
- 108010076667 Caspases Proteins 0.000 claims 1
- 102100029727 Enteropeptidase Human genes 0.000 claims 1
- 108010013369 Enteropeptidase Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 230000007541 cellular toxicity Effects 0.000 claims 1
- 230000001268 conjugating effect Effects 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- -1 fidaxomycin Chemical compound 0.000 claims 1
- 230000008348 humoral response Effects 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000000099 in vitro assay Methods 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000006386 neutralization reaction Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000003405 preventing effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000006337 proteolytic cleavage Effects 0.000 claims 1
- 230000001603 reducing effect Effects 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 101150089436 tcdB gene Proteins 0.000 claims 1
- 230000005945 translocation Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32450310P | 2010-04-15 | 2010-04-15 | |
| US61/324,503 | 2010-04-15 | ||
| US38166910P | 2010-09-10 | 2010-09-10 | |
| US61/381,669 | 2010-09-10 | ||
| PCT/US2011/032713 WO2011130650A2 (en) | 2010-04-15 | 2011-04-15 | Antibodies for the treatment of clostridium difficile-associated infection and disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016131227A Division JP6159854B2 (ja) | 2010-04-15 | 2016-07-01 | クロストリジウム・ディフィシル関連感染症および疾患を治療するための抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013523190A JP2013523190A (ja) | 2013-06-17 |
| JP2013523190A5 true JP2013523190A5 (enExample) | 2014-05-29 |
| JP5965389B2 JP5965389B2 (ja) | 2016-08-03 |
Family
ID=44799348
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013505183A Active JP5965389B2 (ja) | 2010-04-15 | 2011-04-15 | クロストリジウム・ディフィシル関連感染症および疾患を治療するための抗体 |
| JP2016131227A Active JP6159854B2 (ja) | 2010-04-15 | 2016-07-01 | クロストリジウム・ディフィシル関連感染症および疾患を治療するための抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016131227A Active JP6159854B2 (ja) | 2010-04-15 | 2016-07-01 | クロストリジウム・ディフィシル関連感染症および疾患を治療するための抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8986697B2 (enExample) |
| EP (1) | EP2558493B1 (enExample) |
| JP (2) | JP5965389B2 (enExample) |
| KR (1) | KR101820987B1 (enExample) |
| CN (1) | CN102947334B (enExample) |
| AU (1) | AU2011239470B2 (enExample) |
| BR (1) | BR112012026021B1 (enExample) |
| CA (1) | CA2795953C (enExample) |
| ES (1) | ES2757675T3 (enExample) |
| MX (1) | MX339253B (enExample) |
| WO (1) | WO2011130650A2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011239470B2 (en) | 2010-04-15 | 2015-09-10 | Progenics Pharmaceuticals, Inc. | Antibodies for the treatment of Clostridium difficile-associated infection and disease |
| KR101907434B1 (ko) | 2010-09-03 | 2018-10-12 | 발네바 오스트리아 게엠베하 | C. 디피실의 a 독소 및 b 독소 단백질의 분리된 폴리펩타이드 및 이의 용도 |
| US9505847B2 (en) | 2011-08-22 | 2016-11-29 | Cnj Holdings Inc | Clostridium difficile antibodies |
| BR112014006175B1 (pt) * | 2011-09-16 | 2020-02-11 | Ucb Pharma S.A. | Anticorpos capazes de neutralisar as exotoxinas principais tcda e tcdb de clostridium difficile |
| AU2012349753A1 (en) * | 2011-12-08 | 2014-06-19 | Novartis Ag | Clostridium difficile toxin-based vaccine |
| CN102590515B (zh) * | 2012-01-13 | 2014-07-30 | 张春华 | 艰难梭菌外毒素a检测试剂盒及组成该试剂盒的单克隆抗体 |
| CA2862483A1 (en) | 2012-01-23 | 2013-08-01 | Santalis Pharmaceuticals Inc. | Sandalwood oil and its uses related to clostridium infections |
| MX2014010527A (es) | 2012-03-02 | 2014-10-14 | Regeneron Pharma | Anticuerpos humanos para toxinas de clostridium difficile. |
| GB201206070D0 (en) | 2012-04-04 | 2012-05-16 | Health Prot Agency | Clostridium difficile antigens |
| WO2014061783A1 (ja) | 2012-10-19 | 2014-04-24 | 株式会社イーベック | クロストリジウム・ディフィシルの毒素に特異的なヒト抗体もしくはその抗原結合性断片 |
| JP2016501877A (ja) * | 2012-11-28 | 2016-01-21 | シーエヌジェー ホールディングス，インコーポレイテッド | クロストリジウム・ディフィシルに対する抗体 |
| WO2014100740A1 (en) | 2012-12-21 | 2014-06-26 | Seattle Genetics, Inc. | Anti-ntb-a antibodies and related compositions and methods |
| WO2014144292A2 (en) * | 2013-03-15 | 2014-09-18 | Sanofi Pasteur Biologics , Llc | Antibodies against clostridium difficile toxins and methods of using the same |
| EP2986316B1 (en) * | 2013-04-19 | 2023-01-25 | Immuron Limited | Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease |
| CN105451762A (zh) * | 2013-04-22 | 2016-03-30 | 俄克拉荷马州大学评议会 | 艰难梭菌疫苗及使用方法 |
| EP2957570B1 (en) | 2014-06-20 | 2019-04-17 | Immunimed Inc. | Polyclonal antibodies against clostridium difficile and uses thereof |
| US10513552B2 (en) | 2014-06-20 | 2019-12-24 | Immunimed Inc. | Use of polyclonal antibodies against clostridium difficile for treatment of inflammatory bowel disease |
| EP3277706A1 (en) | 2015-03-31 | 2018-02-07 | VHsquared Limited | Polypeptide comprising an immunoglobulin chain variable domain which binds to clostridium difficile toxin b |
| WO2016156474A1 (en) | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Polypeptide comprising an immunoglobulin chain variable domain which binds to clostridium difficile toxin a |
| EP3283103A4 (en) * | 2015-04-15 | 2018-12-05 | Medimmune, LLC | Methods for treating clostridium difficile infection and associated disease |
| GB201509326D0 (en) * | 2015-05-29 | 2015-07-15 | Antibio Tx Aps | Novel use |
| EP3344276B1 (en) | 2015-09-03 | 2020-04-22 | The Board of Regents of the University of Oklahoma | Peptide inhibitors of clostridium difficile tcdb toxin |
| CN119454720A (zh) * | 2016-03-24 | 2025-02-18 | 帕拉特克Spv2有限责任公司 | 用于治疗和预防艰难梭菌感染的方法 |
| US11185555B2 (en) | 2016-04-11 | 2021-11-30 | Noah James Harrison | Method to kill pathogenic microbes in a patient |
| EP3448987A4 (en) * | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| WO2018148537A1 (en) * | 2017-02-10 | 2018-08-16 | Stc. Unm | Recombinant expression systems and products |
| JP7339262B2 (ja) * | 2018-01-12 | 2023-09-05 | アムジェン インコーポレイテッド | Ｐａｃ１抗体及びその使用 |
| GB201807367D0 (en) * | 2018-05-04 | 2018-06-20 | Univ Newcastle | Biomarker |
| RU2694549C1 (ru) * | 2018-08-16 | 2019-07-16 | Федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр здоровья детей" Министерства здравоохранения Российской Федерации (ФГАУ "НМИЦ здоровья детей" Минздрава России) | Способ ведения детей с болезнью Гиршпрунга в периоперационном периоде |
| WO2021219786A1 (en) * | 2020-04-30 | 2021-11-04 | Gottfried Himmler | Anti-toxin secretory iga2 preparation |
| CN111499738B (zh) * | 2020-06-03 | 2022-04-05 | 郑州师范学院 | 一种抗艰难梭菌肠毒素a的抗体 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5292668A (en) | 1981-12-21 | 1994-03-08 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
| US4879218A (en) * | 1982-09-13 | 1989-11-07 | Virginia Tech Intellectual Properties, Inc. | Antibody for C.difficile |
| US6071517A (en) | 1986-07-07 | 2000-06-06 | Medarex, Inc. | Bispecific heteroantibodies with dual effector functions |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5231003A (en) * | 1990-05-11 | 1993-07-27 | Cambridge Bioscience Corporation | Monoclonal antibodies specific for toxin b of clostridium difficile |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| EP0690452A3 (en) | 1994-06-28 | 1999-01-07 | Advanced Micro Devices, Inc. | Electrically erasable memory and method of erasure |
| US20100081792A1 (en) | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
| US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| ES2366626T3 (es) | 2004-02-06 | 2011-10-24 | University Of Massachusetts | Anticuerpos contra toxinas de clostridium difficile y usos de los mismos. |
| CA2580796C (en) | 2004-09-24 | 2013-03-26 | Amgen Inc. | Modified fc molecules having peptides inserted in internal loop regions |
| CA2592015A1 (en) | 2004-12-27 | 2006-07-06 | Progenics Pharmaceuticals (Nevada), Inc. | Orally deliverable and anti-toxin antibodies and methods for making and using them |
| US9963510B2 (en) | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP1820513A1 (en) | 2006-02-15 | 2007-08-22 | Trion Pharma Gmbh | Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies |
| EP2033657A1 (de) | 2007-09-04 | 2009-03-11 | Trion Pharma Gmbh | Intraoperative trifunktionale Antikörper-Applikation zur Prophylaxe intraperitonealer Tumorzelldissemination |
| AU2011239470B2 (en) | 2010-04-15 | 2015-09-10 | Progenics Pharmaceuticals, Inc. | Antibodies for the treatment of Clostridium difficile-associated infection and disease |
-
2011
- 2011-04-15 AU AU2011239470A patent/AU2011239470B2/en active Active
- 2011-04-15 BR BR112012026021-9A patent/BR112012026021B1/pt active IP Right Grant
- 2011-04-15 WO PCT/US2011/032713 patent/WO2011130650A2/en not_active Ceased
- 2011-04-15 CN CN201180024312.0A patent/CN102947334B/zh active Active
- 2011-04-15 ES ES11769680T patent/ES2757675T3/es active Active
- 2011-04-15 US US13/641,315 patent/US8986697B2/en active Active
- 2011-04-15 KR KR1020127029208A patent/KR101820987B1/ko active Active
- 2011-04-15 MX MX2012011926A patent/MX339253B/es active IP Right Grant
- 2011-04-15 CA CA2795953A patent/CA2795953C/en active Active
- 2011-04-15 JP JP2013505183A patent/JP5965389B2/ja active Active
- 2011-04-15 EP EP11769680.7A patent/EP2558493B1/en active Active
-
2015
- 2015-03-09 US US14/642,342 patent/US20150175681A1/en not_active Abandoned
-
2016
- 2016-07-01 JP JP2016131227A patent/JP6159854B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101753553B1 (ko) | 스타필로코커스 아우레우스 감염의 치료 및 예방을 위한 조성물 및 방법 | |
| CN103732621B (zh) | 抗神经生长因子抗体及其制备和使用方法 | |
| KR101721678B1 (ko) | 조건부 활성 항-표피 성장 인자 수용체 항체 및 이의 사용 방법 | |
| RU2687588C2 (ru) | Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas | |
| KR102166083B1 (ko) | 브라디키닌 b1 수용체 리간드에 대한 항체 | |
| JP7257971B6 (ja) | 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用 | |
| RU2682046C1 (ru) | Il-17a-связывающий агент и способы его применения | |
| RU2770209C2 (ru) | Терапевтические антитела против лиганда cd40 | |
| US12227583B2 (en) | Anti-OX40 antibody, antigen-binding fragment thereof, and the pharmaceutical use | |
| RU2013125459A (ru) | АНТИТЕЛА ПРОТИВ БЕЛКА РЕЦЕПТОРА c-Met | |
| JP2024026170A (ja) | 癌を処置するための組成物及び方法 | |
| KR20200113228A (ko) | 항-4-1bb 항체, 이의 항원-결합 단편 및 이의 의학적 용도 | |
| TWI685504B (zh) | 抗gitr抗體、其抗原結合片段及其醫藥用途 | |
| JP7014783B2 (ja) | 抗ｃｄ２７抗体、その抗原結合性フラグメント、およびそのものの医学的使用 | |
| CA2982358A1 (en) | Methods for treating clostridium difficile infection and associated disease | |
| US20240010711A1 (en) | Compositions and methods for treating and preventing staphylococcus aureus infections | |
| RU2012143837A (ru) | АНТИТЕЛА ДЛЯ ЛЕЧЕНИЯ АССОЦИИРОВАННОЙ С Clostridium difficile ИНФЕКЦИИ И ЗАБОЛЕВАНИЯ | |
| EA047070B1 (ru) | Композиции и способы лечения рака | |
| HK40036534A (en) | Heavy chain antibodies binding to cd22 | |
| HK40015379A (en) | Therapeutic anti-cd40 ligand antibodies | |
| HK1229710A1 (en) | Compositions and methods for treating and preventing staphylococcus aureus infections | |
| HK1236389B (en) | Compositions and methods for treating and preventing staphylococcus aureus infections |